ERLANGER Home
HealthLink Plus For Vendors For the Media Physician Relations and Recruitment
975 East Third Street
Chattanooga, TN 37403
423-778-7000
Children's Hospital at Erlanger Erlanger Baroness Campus Erlanger Bledsoe Campus Erlanger East Campus Erlanger North Campus UT Erlanger Physicians Group





Online Prereg
Register for a Class or Event
New Foundations Page
Print   Email

Breast

 

 Adjuvant (Treatment After Surgery) Breast Cancer Trials 

NSABP B-49             Principal Investigator: Larry Schlabach, MD

                                                Co-Investigator: John McCravey, MD and Matt Graham, MD

Title: NSABP B-49 Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer (IRB#:12-029)

NCT #: NCT01547741        Phase: Phase III

Purpose: Drugs used in chemotherapy work in different ways to stop the growth of breast cancer cells, either by killing the cells or by stopping them from dividing. Giving the drugs in different combinations may kill more breast cancer cells. Giving combination chemotherapy after surgery may kill any tumor cells that remain after surgery.

This randomized phase III trial is studying different combination chemotherapy regimens and their side effects and comparing how well they work in treating women with non-metastatic breast cancer.

Drugs possibly given:
Cyclophosphamide
Docetaxel
Doxorubicin hydrochloride
Paclitaxel

Please view complete information about this trial at: http://www.clinicaltrials.gov/ct2/show/NCT01547741?term=B-49&rank=1 

 

S1007                                Principal Investigator: Larry Schlabach, MD

                                                Co-Investigator: John McCravey, MD and Matt Graham, MD

Title: S1007  A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients With 1-3 Positive Nodes, Hormone Receptor-Positive and Her2-Negative Breast Cancer With ONCOTYPE DX Recurrence Score (RS) of 25 or Less (IRB#:11-015)

NCT #: NCT01272037        Phase: Phase III

Purpose:This phase III clinical trial is studying how well giving tamoxifen citrate, anastrozole, letrozole, or exemestane with or without chemotherapy works in treating patients with invasive breast cancer.

Drugs possibly given:
Anastrozole
Exemestane
Letrozole
Tamoxifen citrate
Systemic chemotherapy (drugs chosen by Oncologist)

Please view complete information about this trial at: http://www.clinicaltrials.gov/ct2/show/NCT01272037?term=S1007&rank=1

S1207             Principal Investigator: Larry Schlabach, MD

                              Co-Investigator: John McCravey, MD and Matt Graham, MD

Title: S1207 Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and HER2/NEU Negative Breast Cancer (IRB #13-010)

NCT #: NCT01674410        Phase: Phase III

Purpose:  This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.
                                                                                                                                                                                                                                                                                                            Drugs possibly given:
Anastrozole
Everolimus                                                                                                                                                                                                                                                                             Exemestane
Goserelin acetate
Letrozole
Leuprolide acetate
Tamoxifen citrate                                                                                                                                                                                                                                                                                        Placebo                                                                                                                                                                                                                                                                          

Please view complete information about this trial at: http://www.clinicaltrials.gov/ct2/show/NCT01674140?term=s1207&rank=1